Radiation Treatment for Bladder Cancer with Misonidazole
Author Information
Author(s): R.P. Abratt, P. Craighead, V.B. Reddi, L.A. Sarembock
Primary Institution: University of Cape Town
Hypothesis
Does the addition of oral and intravesical misonidazole improve outcomes in bladder cancer patients receiving radiation therapy?
Conclusion
The study found no significant improvement in treatment outcomes with the addition of misonidazole to radiation therapy for bladder cancer.
Supporting Evidence
- The complete response rate at cystoscopy at 6 months was 63% for NO MISO and 69% for PLUS MISO.
- The 5-year survival rate was 41% for NO MISO and 48% for PLUS MISO.
- The 5-year local control rate with bladder preservation was 46% for NO MISO and 36% for PLUS MISO.
- Two patients in the PLUS MISO arm experienced grade 3 late bowel complications.
Takeaway
Doctors wanted to see if a drug called misonidazole could help people with bladder cancer when combined with radiation, but it didn't make a difference in the results.
Methodology
Patients with T2 grade 3 and T3 bladder cancer were randomized to receive either radiation alone or radiation with misonidazole, with follow-up assessments at 6 months and 5 years.
Limitations
The study had a relatively low number of patients, which may have limited the ability to detect significant differences.
Participant Demographics
Patients were less than 75 years old, with a mean age of 65 in the NO MISO group and 62 in the PLUS MISO group.
Statistical Information
P-Value
p<0.001 for complete response survival rates
Want to read the original?
Access the complete publication on the publisher's website